NewsBenzingaCognition Therapeutics 就路易体痴呆 III 期研究的关键要素与美国 FDA 达成一致，包括患者选择、剂量、疗程和终点 Cognition Therapeutics 就路易体痴呆 III 期研究的关键要素与美国 FDA 达成一致，包括患者选择、剂量、疗程和终点 Benzinga 2026.10.22 10:02 (GMT+0) Open on Benzinga Other news Canaccord Genuity Maintains Hold on Estee Lauder Cos, Raises Price Target to $109 Zurn Elkay Water Solutions Raises Quarterly Common Stock Dividend From $0.11 To $0.13 Per Share Blackstone CEO Sounds Alarm on AI Supply Crunch: 'Seldom in My Career Have I Seen' Anything Like It AbbVie’s Skin Disease Drug Hits Phase 3 Goal, but Efficacy Falls Short of Benchmarks: Analyst Trump Administration Announces Major Investment In American Fertilizer Manufacturing To Strengthen National Security And Support Farmers; Intrepid Potash To Receive $139M In Proposed Financing To Build Sulfate Of Potash Production Site Near Carlsbad... 'Salesforce Customers Brace For New Fees to Use Claude in Its Apps' - The Information
Trump Administration Announces Major Investment In American Fertilizer Manufacturing To Strengthen National Security And Support Farmers; Intrepid Potash To Receive $139M In Proposed Financing To Build Sulfate Of Potash Production Site Near Carlsbad...
